WWW.IJRPR.COM

**International Journal of Research Publication and Reviews**

Journal homepage: www.ijrpr.com ISSN 2582-7421

# Global Perspectives on Liver Diseases: Burden, Management, and Emerging Therapies

***Subba. Dil***

*Assistant Professor, Department of Pharmacy, School of Pharmacy, Sharda University, Greater Noida, 201310, Uttar Pradesh, India.*
***Email ID**: dilprasadsubba60@gmail.com*

**ABSTRACT**

Liver diseases are a major global health issue, which includes the aforementioned viral hepatitis, non-alcoholic fatty liver disease (NAFLD), cirrhosis, and hepatocellular carcinoma (HCC). These come up due to multiple reasons, such as virus attacks, genetic factors, metabolism problems, and lifestyle. Over the past few years, Non-Alcoholic Fatty Liver Disease (NAFLD) has become the leading liver ailment, which makes up 59% of chronic liver diseases at a global level, with metabolic dysfunction being the main problem. Besides, liver diseases are still the leading causes of death with cirrhosis and liver-related complications accounting for more than 1 million deaths each year. The article makes a critical review of current pharmacological and non-pharmacological management approaches, points to progress in diagnostic tools like machine learning, and also the adherence of patients to lifestyle recommendations. The discussion is about the increasing demand for individualised medicine, inter-professional approaches, and health protection plans to lessen the load of liver diseases.

**Keywords**: Liver diseases, NAFLD, cirrhosis, hepatocellular carcinoma, adverse drug reactions, lifestyle modification, pharmacotherapy.

## Introduction

Liver diseases range from a viral hepatitis infection to the severe liver conditions of cirrhosis and hepatocellular carcinoma (HCC). They are worldwide health threats[1][2]. The diseases' origin is not simple since viruses, particularly hepatitis B and C, are leading factors of acute and chronic liver damage[2]. Besides this, the metabolic liver diseases like α1-antitrypsin deficiency, Wilson disease, and hereditary hemochromatosis can cause cirrhosis and liver failure too[3]. The increasing NAFLD prominence due to the changing lifestyle is an example of the consequences of modern life regarding liver health[1]. Liver diseases are many, but the one that is most dangerous is the fact that they often develop without showing many symptoms, being discovered only in advanced stages which is the case for most of them[4]. New Methods, like machine learning models, are being examined to increase the chances for success in the early treatment of diseases, which is the main reason that individual treatment should be the focus of medicine in working with these intricate cases[4][1]. The causes of liver diseases are many, including the infectious, genetic, environmental, and lifestyle factors. The major causative agents of acute-on-chronic liver failure and primary liver cancer are viral infections with hepatitis B and C, after alcohol consumption and non alcoholic steatohepatitis[5][6]. Genetic susceptibilities and metabolic disorders are traits made for the little ones, and in those conditions like biliary atresia different metabolic diseases are the most common[7]. On the other hand, environmental stresses like autoimmune diseases, malnutrition, trauma, and drug toxicity might also be the reasons for liver damage[8Recent developments in success-oriented liver disease rehabilitation require the identification of etiological factors, that impact disease course and the probability of recovery[9]. The non-alcoholic fatty liver disease (NAFLD) spectrum includes liver disease that starts with a healthy liver and progresses to liver injury. The first stage is when fat is in less than five per cent of the hepatocytes. The second stage, the non-alcoholic fatty liver stage (NAFL), is when Steatosis with liver fat builds up in the hepatocyte by over five per cent. Further progression may cause non-alcoholic steatohepatitis (NASH), which is the term for conditions involving inflammation, ballooning, and fibrosis. NASH can progress to cirrhosis, which makes the liver stubbornly scar, and fibrosis and then organ failure, with difficulties of the organ. Cirrhotic livers are at a greater danger of getting hepatocellular carcinoma, which may be a reason for liver transplant or even lead to death[10].




*Figure. BioRender (2020). Non-Alcoholic Fatty Liver Disease (NAFLD) Spectrum.*




*Figure 2: Dipiro(2013), Pharmacotherapy for liver diseases approaches.*

The currently available pharmacotherapy for liver disorders, particularly cirrhosis and non-alcoholic fatty liver disease (NAFLD), is a main staple in the treatment of the underlying conditions and control of the secondary diseases. Concerning the treatment of cirrhosis, the use of diuretics, such as spironolactone is the standard practice to treat uncomplicated ascites, while beta-blockers of the non-selective category are effective in the reduction of the risk of re-bleeding from the varices.

On the other hand, they could be detrimental to the renal function of the patients with the advanced forms of the disease[11][12].The other drug, rifampicin, is essential for the prevention of bacterial peritonitis and for the treatment of hepatic encephalopathy[12]. In NAFLD, the best successful medical treatments are pioglitazone and vitamin E which act by targeting insulin resistance and oxidized stress respectively[13][14]. New therapeutic medicines, including glucagon-like peptide-1 receptor antagonists, (like semaglutide) which are very effective in improving the liver histopathology in non-alcoholic steatohepatitis (NASH).

The treatment of liver diseases includes a variety of pharmacological techniques that are used in the case of chronic hepatitis, cirrhosis, drug-induced liver injury (DILI) and so on. Traditional herbal remedies, such as those made from Astragalus root and Ganoderma lucidum, have been effective in treating early cirrhosis and chronic hepatitis by enhancing liver function and blood circulation[16]. On the other hand, DILI management remains complicated as many of the drugs that are usually prescribed have hepatotoxic effects. Therefore, it is important to carry out careful drug selection and adjust the dosage based on the individual's liver function[17][18]. Magnesium isoglycyrrhizinate, which has been shown to have the ability to normalize liver enzyme levels, is among the new therapies pointed out in recent studies, while further research is needed to verify this.[18]. Furthermore, the contribution of alcohol to liver health is enormous, with alcohol-related liver disease being one of the major causes of cirrhosis, especially in the areas

where the consumption of alcohol is high[19]. To sum up, effective liver disease management requires a multifaceted approach that not only combines traditional methods but also novel therapies.

## Managements

Management of liver disease refers to a wide-ranging approach that is specific to the patient's condition and the underlying causes of the disease. For non alcoholic fatty liver disease (NAFLD), the strategies of multidisciplinary diagnosis and treatment (MDT) have resulted in better prevention and treatment outcomes, even though there are some obstacles in implementation[20]. Regarding liver cirrhosis, the treatment mainly focuses on the modification of the risk factors such as alcohol abstinence and lifestyle modifications. Nevertheless, patients are also regularly monitored for complications like hepatocellular carcinoma[21]. The management of Alcoholic liver disease is also stage-dependent, underlining the significance of abstinence, anti-inflammatory therapies, and nutritional support along with the investigation of new treatment pathways[22]. The establishment of standardized evaluation tools for occupational health nurses has been developed with the aim of enhancing the quality of care provided to patients with liver disease[23]. In summary, these strategies stress out the need for a thorough and unique approach to liver disease management.

## Life modification

Lifestyle modifications are a key factor in overcoming liver conditions especially metabolic dysfunction associated with steatosis liver diseases (MASLD) and non-alcoholic fatty liver disease (NAFLD). Traditionally, this has involved reducing caloric intake, exercising more, and educating oneself, all of which have been proven to have positive effects on both the liver and the body. As an example, a multifaceted lifestyle intervention program led to a marked decrease in body weight, liver enzymes, and hepatic steatosis in people with an excessive hepatic steatosis index[24]. In the same vein, structured exercise and healthful nutritional practices were linked to lowered level of liver enzymes and body mass in NAFLD patients[25]. Besides, embarking on a Low-Glycemic-Index Mediterranean Diet coupled with exercise led to a remarkable decrease in liver fibrosis scores[26]. Collectively, these research studies reveal the power of lifestyle changes in the promotion of liver health and preventing the development of related comorbidities[27][28].

## Adverse Drug Reactions

Adverse reactions that have been linked with liver diseases, mainly drug-induced liver injury (DILI), pose important problems in the clinic. Drug-Induced Liver Injury (DILI) can happen due to the type of hepatocellular, cholestatic, or mixed injury, and the symptoms of which are the elevated levels of liver enzymes such as alanine aminotransferase and alkaline phosphatase[29]. The probability of experiencing liver-related adverse drug reactions (L-ADRs) is higher among older patients thus it has been reported that for every decade increase in age after 52 years the chances of L-ADRs increase by 33%[30]. The common symptoms are jaundice, abdominal pain, and nausea which are the reasons why it is difficult to diagnose these diseases because these people also experience nonspecific symptoms[31]. Some classes of medications, above all antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), and antituberculosis medicines, are the ones that are often blamed for DILI, a situation that is serious enough to cause acute liver failure and need a liver transplant procedure[32][33]. Proper treatment requires the withdrawal of the drug that is causing the reaction and the use of medicine for the symptoms. Thus, thorough must be carried out as some sections of the population are more vulnerable[34][35].

## Complications

Complications of liver disease encompass a wide range of serious health issues, mainly because the ailment is progressing to the stage of cirrhosis and then finally end-stage liver disease (ESLD). Some patients may face acute decompensation which is further aggravated by conditions such as hepatopulmonary syndrome, hepatorenal syndrome, and hepatic carcinoma. which in turn, greatly intensify the rates of morbidity and mortality[36][37]. Common complications include neuronal degeneration in the liver, muscle wasting, a buildup of fluid in the abdomen, and bleeding due to the esophagus and stomach varices, which all comprise a poor quality of life[38]. Moreover, along with the above-mentioned complications, patients may also experience pruritus and fatigue, which might even appear before liver disease is confirmed[39]. The treatment of these complications is often directed towards liver transplantation, however, many patients are in a dilemma like they are on an organ waiting list or they are ineligible due to co-morbid conditions[40]. Overall, the weight of the complications accentuates how important it is to follow up with the liver disease patients with multi-faceted care strategies and ensuring the patients are taken care of properly[41].

## Percentage of mortality of liver disease.

Meantime last year liver disease-related mortality figures have become a normative rather, with liver diseases contributing approximately 4% to all deaths happening all over the world, thus equating to those almost 2 million deaths every year[42]. Chronic liver disease (CLD) is one of the most bone-biting problems that affect around 1.5 billion people globally, among which non-alcoholic fatty liver disease (NAFLD) is the most widespread, comprising 59% of all cases[43]. The year 2022 has recorded an unprecedented level of liver transplants thus signaling people's increasing awareness of the serious nature of liver disease that is related especially to alcohol usage. It remains the foremost reason among transplant candidates[44]. The injury rates associated with liver cirrhosis are so high that each year over 1 million deaths are attributed to it which in turn has made it a focal area of intervention for public

health[45]. Overall, no matter how difficult the burden of liver disease might be, new researches and strategies will still be necessary to reduce its effects on people's lives[46].

**Methods and materials:** This literature review utilized PubMed, Google Scholar, and ResearchGate to identify peer-reviewed articles and clinical studies from 2018 to 2024. Search terms included "liver diseases," "NAFLD management," "liver disease mortality," "adverse drug reactions," and "pharmacotherapy for cirrhosis." Inclusion criteria focused on articles discussing aetiology, management strategies, complications, and emerging therapies for liver diseases. Articles were screened for relevance and quality, with a total of 85 articles reviewed in depth.

## Discussion and Results




*Figure 3. Percentage distribution of chronic liver diseases*

In Figure 3, the pie chart shows the distribution percentages of chronic liver diseases in which NAFLD represents 59% and the rest of the liver diseases comprise the remaining 41% according to the data of 2022–2024.

**Burden of Liver Diseases**:Liver diseases constitute around 4% of worldwide fatalities which means there are 2 million deaths per year. NAFLD is the major reason for chronic liver disease which afflicts 1.5 billion people across the globe. Alcohol-caused liver disease is still a major cause of liver transplantations with the U.S. transplant figures touching the highest ever in 2022. Cirrhosis death rates are more than 1 million every year which calls for immediate effective intervention.

## Management Strategies

1. Pharmacotherapy:Cirrhosis: Spironolactone and non-selective beta-blockers are the usual treatments for complications like ascites and variceal bleeding, respectively.NAFLD: Pioglitazone and vitamin E are designed to combat metabolic dysfunction, while one of the new therapies namely semaglutide has shown positive results in patients in terms of liver histology. Adverse Drug Reactions (DILI): Antibiotics, NSAIDs, and antituberculosis drugs are the main drugs which cause liver injuries after drug usage; therefore, they should be closely monitored and the drug responsible should be discontinued.

2. Lifestyle Modifications:Structured exercise and dietary modifications have been established that they enhance the liver function, decrease the fibrosis scores, and the levels of the liver enzymes. Switching to a Mediterranean diet and increased physical activity are two of the most effective treatments for metabolic-associated liver diseases.

3. Emerging Approaches: The machine learning models that can be used to support the personal treatment of patients with liver disease by performing early detection of such diseases and predicting disease progression are being developed.

**Complications of Liver Diseases**: The vascular and hepatic pathologies accompanying the development of cirrhosis or hepatocellular carcinoma include the hepatic encephalopathy, hepatorenal syndrome, and esophagogastric variceal hemorrhage. End-stage liver disease patients can be treated with liver transplantation, yet the two problems organ availability and patient eligibility are still the main obstacles.

**Conclusion**: Liver diseases represent a complex global challenge that requires a multifaceted approach to management. Non-alcoholic fatty liver disease, as the most common liver disorder, reflects how modern lifestyles affect liver health. Progresses made in the areas of pharmacotherapy, early detection with machine learning, and lifestyle interventions give the hope for a better turnaround. Nonetheless, the addressing of the high mortality rates associated

with liver cirrhosis and the end-stage liver disease complications still needs further research and public health measures. Personalized treatment and multidisciplinary care strategies are still the two main things in reducing the global impact of liver diseases.

**Reference**


1. Hina, Wazir., Marium, Abid., Binish, Essani., Hira, Saeed., Muhammad, Ahmad, Khan., Fnu, Nasrullah., Usama, Qadeer., Ayesha, Khalid., Giustino, Varrassi., Muhammad, Ali, Muzammil., Areeba, Maryam., Abdul, Rehman, Shah, Syed., Abdul, Ahad, Shah., Satish, Kinger., Farhan, Ullah. (2023). 2. Diagnosis and Treatment of Liver Disease: Current Trends and Future Directions. Cureus, doi: 10.7759/cureus.49920.
2. Meng, Ren., Chen, Lu., Mingwei, Zhou., Xiaobing, Jiang., Xiaodong, Li., Ningning, Liu. (2024). 5. The intersection of virus infection and liver disease: A comprehensive review of pathogenesis, diagnosis, and treatment.. Wires Mechanisms Of Disease, doi: 10.1002/wsbm.1640.
3. Angela, Cheung., William, Sánchez. (2024). 3. Metabolic Liver Diseases. doi: 10.1093/med/9780197679753.003.0030.
4. Jiajun, Lu. (2023). 4. Research on Prediction of Liver Disease Based on Machine Learning Models. Highlights in Science Engineering and Technology, doi: 10.54097/hset.v68i.11926.
5. Ankur, Kumar., Amresh, Kumar, Singh., Mr., Vivek, Gaur., Rahul, Singh. (2024). 2. Microbial pathogenesis of liver diseases in present time. doi: 10.58532/v3bams11p3ch3.
6. Qing-Qing, Xing., Jing-Mao, Li., Xuan, Dong., Dan, Zeng., Zhi-Jian, Chen., Xiao-Yun, Lin., Jin-Shui, Pan. (2022). 5. Socioeconomics and attributable etiology of primary liver cancer, 1990-2019. World Journal of Gastroenterology, doi: 10.3748/wjg.v28.i21.2361.
7. Jismy, Karakkattu., Roshni, Pr. (2016). 4. Etiology for liver diseases in pediatric population. Asian Journal of Pharmaceutical and Clinical Research, doi: 10.22159/AJPCR.2017.V10I1.14121.
8. Chunlei, Chen., Wenrui, Wu., Yongtao, Li. (2021). 1. Etiology of Liver Injury. doi: 10.1007/978-981-15-5984-6_5.
9. Alberto, Quaglia., Venancio, Avancini, Ferreira, Alves., Charles, Balabaud., Prithi, S., Bhathal., Paulette, Bioulac-Sage., James, M., Crawford., Amar, P., Dhillon., Linda, D., Ferrell., Maria, Guido., Prodromos, Hytiroglou., Yasuni, Nakanuma., Valérie, Paradis., Dale, C., Snover., Neil, D., Theise., Swan, N., Thung., Wilson, M., S., Tsui., Dirk, J., van, Leeuwen. (2016). 3. Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation. Histopathology, doi: 10.1111/HIS.12957.
10. BioRender (2020). Non-Alcoholic Fatty Liver Disease (NAFLD) Spectrum. https://app.biorender.com/biorender-templates/figures/all/t-5f7b2888f7396700abd2cf23-non-alcoholic-fatty-liver-disease-nafld-spectrum.
11. T., M., Bentsa. (2021). 1. Pharmacotherapy of liver cirrhosis and its complications. doi: 10.37987/1997-9894.2021.2(248).229010.
12. David, Kockerling., Rooshi, Nathwani., Roberta, Forlano., Pinelopi, Manousou., Benjamin, H., Mullish., A., Dhar. (2019). 2. Current and future pharmacological therapies for managing cirrhosis and its complications.. World Journal of Gastroenterology, doi: 10.3748/WJG.V25.I8.888.
13. Sang, Hoon, Park. (2014). 3. Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. The Korean Journal of Internal Medicine, doi: 10.3904/KJM.2014.86.4.425.
14. Deepu, David., Chundamannil, E., Eapen. (2021). 4. What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease. Journal of clinical and experimental hepatology, doi: 10.1016/J.JCEH.2020.09.001.
15. Young, Chang., Soung, Won, Jeong., Jae, Young, Jang. (2023). 5. Recent Updates on Pharmacologic Therapy in Nonalcoholic Fatty Liver Disease.. Clinical and molecular hepatology, doi: 10.3350/cmh.2023.0356.
16. Baoxian, Zhang. (2006). 2. Medicament for treating liver disease.
17. Mirjana, Stanic, Benic., Lana, Nežić., Vesna, Vujić-Aleksić., Liliana, Mititelu-Tartau. (2022). 3. Novel Therapies for the Treatment of Drug-Induced Liver Injury: A Systematic Review. Frontiers in Pharmacology, doi: 10.3389/fphar.2021.785790.
18. Balthasar, L., Hug., Christian, Surber., David, W., Bates. (2012). 4. Use of hepatotoxic drugs in chronic liver disease.. Journal of Patient Safety, doi: 10.1097/PTS.0B013E3182482DF2.
19. Rais, A., Ansari. (2013). 5. Drugs Needed for Treatment of Liver Cirrhosis. Journal of Drug Metabolism and Toxicology, doi: 10.4172/2157-7609.1000E117.
20. C., H., Yu. (2023). 1. [MDT management of nonalcoholic fatty liver disease].. doi: 10.3760/cma.j.cn501113-20230810-00050.
21. David, Semela., Samuel, Henz. (2023). 2. [CME: Outpatient Management of Patients with Liver Cirrhosis].. Praxis, doi: 10.1024/1661-8157/a004042.

22. David, Kershenobich., Dana, Lau, Corona., Ruben, Kershenovich., Gabriela, Gutierrez-Reyes. (2011). 4. Management of Alcoholic Liver Disease: An Update. Alcoholism: Clinical and Experimental Research, doi: 10.1111/J.1530-0277.2010.01402.X.

23. Moon-Hee, Jung., Chung-Min, Cho. (2000). 5. A Study on an Evaluation Tool for the Management of Liver Disease by Occupational Health Management Agencies. Journal of Occupational Health, doi: 10.1539/JOH.42.72.

24. Panchali, Moitra., Ashwin, Deshmukh., Pankaj, Tailor., Pooja, P., Khedekar., Jagmeet, Madan. (2024). 1. Effects of a multicomponent lifestyle modification intervention on liver function, lipid profile, and body composition in adults with elevated hepatic steatosis index. Proceedings of the Nutrition Society, doi: 10.1017/s0029665124004580.

25. Amal, El-Abbassy., Engy, E., Eldoushy., Hemat, Mostafa, Amer., Elham, Elzyen. (2024). 2. Efficacy of Lifestyle Interventions on Body Weight and Elevated Liver Enzymes among Patients with Non-Alcoholic Fatty-Liver Disease. International Egyptian Journal of Nursing Sciences and Research (Online), doi: 10.21608/ejnsr.2024.334334.

26. Ritanna, Curci., Antonella, Bianco., Isabella, Franco., Caterina, Bonfiglio., Angelo, Campanella., Antonella, Mirizzi., Vito, Giannuzzi., Raffaele, Cozzolongo., Nicola, Veronese., Alberto, Rubén, Osella. (2023). 3. Lifestyle Modification: Evaluation of the Effects of Physical Activity and Low-Glycemic-Index Mediterranean Diet on Fibrosis Score. Nutrients, doi: 10.3390/nu15163520.

27. Tso-Tsai, Liu., He, Qiu., Shi-Yu, Liu., Chieh, Chien., Jen-Hung, Wang., Ming-Wun, Wong., Chih-Hsun, Yi., Lin, Lin., Wei-Yi, Lei., Shu-Wei, Liang., Jui-Sheng, Hung., Jee-Fu, Huang., Chien-Lin, Chen., Ma, Ai, Thanda, Han. (2022). 4. Modifications decrease hepatic steatosis in Taiwanese with metabolic-associated fatty liver disease. Kaohsiung Journal of Medical Sciences, doi: 10.1002/kjm2.12580.

28. V.I., Didenko., V.B., Yagmur., S.L., Melanich., L.V., Demeshkina., O., V., Simonova. (2023). 5. Lifestyle modification in the treatment of refractory gastroesophageal reflux disease and non-alcoholic fatty liver disease. A clinical case. Гастроентерологія, doi: 10.22141/2308-2097.56.4.2022.517.

29. Alejandra, Cano, Paniagua., Pedro, Amariles. (2017). 4. Hepatotoxicity by Drugs. doi: 10.5772/INTECHOPEN.72005.

30. Yan-Zhong, Han., Yuming, Guo., Peng, Xiong., Fei-Lin, Ge., Jing, Jing., Ming-Yue, Niu., Xu-Yuan, Zhao., Zhaofang, Bai., Hai-bo, Song., Xiaohe, Xiao., Jia-Bo, Wang. (2022). 2. Age-Associated Risk of Liver-Related Adverse Drug Reactions. Frontiers in Medicine, doi: 10.3389/fmed.2022.832557.

31. Alejandra, Cano, Paniagua., Pedro, Amariles. (2017). 4. Hepatotoxicity by Drugs. doi: 10.5772/INTECHOPEN.72005.

32. Ervilla, Dass. (2020). 3. A brief review on Drug-induced hepatotoxicity: Use of hepatoprotective agents. doi: 10.18231/J.IJCAAP.2020.004.

33. Andrea,. Carlin-Ronquillo., Claudia, Alvizuri, Gómez., Carlos, García, Encinas. (2022). 5. Adverse reactions to antituberculosis drugs presenting as DRESS syndrome and acute liver failure.. Revista de Gastroenterología del Perú, doi: 10.47892/rgp.2022.422.1344.

34. F., Schaffner. (1975). 1. Hepatic drug metabolism and adverse hepatic drug reactions.. Veterinary Pathology, doi: 10.1177/030098587501200206.

35. Alejandra, Cano, Paniagua., Pedro, Amariles. (2017). 4. Hepatotoxicity by Drugs. doi: 10.5772/INTECHOPEN.72005.

36. A., Holvast., H., J., Verkade. (2019). 1. Complications of Liver Cirrhosis. doi: 10.1007/978-3-319-96400-3_18.

37. Nwe, Ni, Than. (2017). 3. Pulmonary Complications of Liver Cirrhosis: A Concise Review. doi: 10.5772/INTECHOPEN.68620.

38. Anne, M, Larson. (2015). 5. Palliative Care for Patients with End-Stage Liver Disease. Current Gastroenterology Reports, doi: 10.1007/S11894-015-0440-6.

39. Nora, V., Bergasa. (2022). 4. Complications of Liver Disease. doi: 10.1007/978-1-4471-4715-2_15.

40. Anne, M, Larson. (2015). 5. Palliative Care for Patients with End-Stage Liver Disease. Current Gastroenterology Reports, doi: 10.1007/S11894-015-0440-6.

41. Nora, V., Bergasa. (2022). 4. Complications of Liver Disease. doi: 10.1007/978-1-4471-4715-2_15.

42. Krushna, Baviskar., Aniket, Kshirsagar., Hemant, Raut., Misbah, Shaikh. (2024). 1. Overview: Global burden of liver disease. International journal of pharmaceutical chemistry and analysis, doi: 10.18231/j.ijpca.2024.001.

43. Yao-Chun, Hsu. (2023). 3. Uncovering the Silent Killer: Research Highlights on Chronic Liver Diseases. Digestive Diseases, doi: 10.1159/000530349.

44. Allison, J., Kwong., W., R., Kim., John, R., Lake., David, P., Schladt., Erin, M., Schnellinger., Katrina, Gauntt., Meghan, McDermott., Samantha, Weiss., Dzhuliyana, Handarova., J., Snyder., Ajay, K., Israni. (2024). 2. OPTN/SRTR 2022 Annual Data Report: Liver.. American Journal of Transplantation, doi: 10.1016/j.ajt.2024.01.014.

45. Allison, J., Kwong., W., R., Kim., John, R., Lake., David, P., Schladt., Erin, M., Schnellinger., Katrina, Gauntt., Meghan, McDermott., Samantha, Weiss., Dzhuliyana, Handarova., J., Snyder., Ajay, K., Israni. (2024). 2. OPTN/SRTR 2022 Annual Data Report: Liver.. American Journal of Transplantation, doi: 10.1016/j.ajt.2024.01.014.

46. Ian, A., Rowe. (2017). 5. Lessons from Epidemiology: The Burden of Liver Disease. Digestive Diseases, doi: 10.1159/000456580.

47. Nimzing, Gwamzhi, Ladep., Sheikh, Mohammad, Fazle, Akbar., Mamun, Al, Mahtab. (2019). 4. Global Epidemiology of Chronic Liver Disease. doi: 10.1007/978-3-319-94355-8_5.